In our clinical cohort, we confirmed that SCD and FBN1 expression was significantly upregulated CXXC5 was significantly downregulated in CML, and NME8 and DMXL2 expression were not significantly different due to the small sample size (Figure 6A). This evidence concerns the gene CXXC5 and chronic myelogenous leukemia, BCR-ABL1 positive.